Table 2.
Hazard ratios of BRAF V600E/RAS or TERT promoter mutations each alone or their coexistence for the recurrence of PTC
| Mutations | Recurrence | Recurrence per 1,000 Person-Years (95% CI) | Unadjusted Hazard Ratios (95% CI) |
Adjustment 1 Hazard Ratios (95% CI) |
Adjustment 2 Hazard Ratios (95% CI) |
Adjustment 3 Hazard Ratios (95% CI) |
|
|---|---|---|---|---|---|---|---|
| BRAF | No mutation | 6/87 (6.9) | 22.15 (9.94–49.25) | 1 | |||
| BRAFV600E mutation only | 22/154 (14.3) | 35.5 (23.14–54.44) | 1.88 (0.76–4.63) | 1.84 (0.74–4.56) | 1.36 (0.5–3.7) | 1.34 (0.43–4.17) | |
| TERT mutation only | 1/5 (20) | 154.27 (21.73–1095.16) | 5.82 (0.64–52.64) | 6.24 (0.65–60.10) | 0.90 (0.05–15.55) | 25.30 (0.52–1241) | |
| BRAFV600E+TERT mutations | 7/19 (36.8) | 106.94 (50.98–224.31) | 4.75 (1.58–14.29) | 6.59 (1.55–27.94) | 5.46 (0.71–41.97) | 71.36 (1.11–4560) | |
|
| |||||||
| RAS | No mutation | 6/87 (6.9) | 22.15 (9.94–49.25) | 1 | |||
| RAS mutation only | 3/34 (8.8) | 31.62 (10.20–98.03) | 1.51 (0.36–6.34) | 1.44 (0.34–6.06) | 0.65 (0.11–3.77) | 0.35 (0.04–2.82) | |
| TERT mutation only | 1/5 (20) | 154.27 (21.73–1095.16) | 5.82 (0.64–52.64) | 6.24 (0.65–60.10) | 0.9 (0.05–15.55) | 25.30 (0.52–1241) | |
| RAS+TERT mutations | 6/6 (100) | 1173 (526.99–2610.97) | 39.04 (10.56–144.3) | 106.76 (15.30–744.49) | 89.88 (8.89–909.14) | 138.0 (5.75–3313) | |
|
| |||||||
| BRAF/RAS | No mutation | 6/87 (6.9) | 22.15 (9.94–49.25) | 1 | |||
| BRAF V600E/RAS mutation only | 25/189 (13.2) | 34.86 (23.36–52.01) | 1.77 (0.72–4.31) | 1.74 (0.71–4.24) | 1.3 (0.48–3.5) | 1.24 (0.42–3.66) | |
| TERT mutation only | 1/5 (20) | 154.27 (21.73–1095.16) | 5.82 (0.64–52.64) | 6.24 (0.65–60.10) | 0.90 (0.05–15.55) | 25.30 (0.52–1241) | |
| BRAF V600E/RAS+TERT mutations | 13/25 (52) | 184.2 (106.96–317.28) | 8.17 (3.09–21.58) | 12.44 (3.33–46.56) | 13.16 (2.39–72.42) | 14.71 (2.79–77.61) | |
The “BRAF” group excluded patients with RAS mutations, the “RAS” group excluded patients with BRAF mutation, and the “BRAF/RAS” group included all the patients regardless of the BRAF and RAS mutation status. Hazard ratio and 95% CI were calculated using Cox regression for the comparison of the indicated mutation group with the group harboring neither mutation. Adjustment 1 was made for patient age at diagnosis and sex. Adjustment 2 was made for patient age at diagnosis, sex, multifocality, tumor size, extrathyroidal invasion and lymph node metastasis. Adjustment 3 was made for patient age at diagnosis, sex, multifocality, tumor size, extrathyroidal invasion, lymph node metastasis and medical center.